MAY 01, 2018 1:36 PM PDT

Ditching Mammograms for Dye-Based Breast Cancer Diagnosis

WRITTEN BY: Kara Marker

Move over, mammograms. University of Michigan scientists have a new solution for diagnosing breast cancer that’s possibly more accurate, less invasive, and less uncomfortable. With a pill that delivers a dye to illuminate tumors under infrared light, determining the difference between benign and malignant could become easier than ever before.

Tumors are targeted by a molecule that carries a fluorescent imaging agent in order to make earlier and more accurate breast cancer diagnoses. Credit: Evan Dougherty/Michigan Engineering Communications & Marketing

Many women undergo unnecessary diagnostic tests only to find that their tumor is harmless. The new technology might improve the chances that invasive approaches like surgery and chemotherapy can be reserved for malignant tumors that require this step. Additionally, scientists want to limit the malignant tumors that go unnoticed because thick breast tissue hides lumps. And of course, limiting the number of unnecessary tests will help avoid unnecessary costs.

"We overspend $4 billion per year on the diagnosis and treatment of cancers that women would never die from," explained study leader Greg Thurber, PhD.

The new diagnostic method provides an alternative to mammography, which is uncomfortable for many women and which experts from the study say is imprecise. Mammography provides an x-ray image of the breast, obtained by flattening the breast against the mammogram machine.

University of Michigan researchers, led by Thurber, developed a pill, taken orally by the patient being tested, that delivers a dye responding to infrared light. The dye tags a molecule commonly found on tumor cells and in the surrounding environment. The information obtained from this test can answer the most important question: benign or malignant?

While developing the new diagnostic system, researchers came across issues with creating a pill to carry the dye to the tumor.

"To get a molecule absorbed into the bloodstream, it needs to be small and greasy,” Thurber explained. “But an imaging agent needs to be larger and water-soluble. So you need exact opposite properties.”

They found their solution in a targeting molecule originally designed by Merck for treating cancer. While the molecule didn’t work for their purposes, it did work for the University of Michigan scientists. With this targeting molecule incorporated, the pill can successfully travel through the stomach to the liver and into the bloodstream.

For now, researchers have only shown the diagnostic method to be effective and safe in mice, but further studies are definitely on the horizon.

The present study was published in the journal Molecular Pharmaceutics.

Sources: American Cancer Society, University of Michigan

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 09, 2019
Neuroscience
OCT 09, 2019
Elderly Depression Remains Consistant As Antidepressant Use Doubles
  A new study from the University of East Anglia finds that despite a 2-fold increase in antidepressant use, depression among individuals 65 and older...
OCT 18, 2019
Clinical & Molecular DX
OCT 18, 2019
AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia
To support the validation and verification of new assays in oncology testing, Thermo Fisher Scientific with AcroMetrix control products provides innov...
NOV 26, 2019
Clinical & Molecular DX
NOV 26, 2019
Looking into the eyes of MS patients for personalized therapies
Blurred or double vision, and in extreme cases, complete vision loss are amongst the earliest symptoms of multiple sclerosis (MS). In this devastating dise...
NOV 14, 2019
Chemistry & Physics
NOV 14, 2019
Examining the Squirrelly Ones: Wearable MEG Scanner that Suits Pediatric Patients
In a recent study, a joint research team at the University of Nottingham, University of Oxford, and University College London successfully tested a ne...
JAN 22, 2020
Clinical & Molecular DX
JAN 22, 2020
Biosignatures detect TB infections months before symptoms appear
What if there was a test that could detect tuberculosis six months before symptoms appear? Researchers at the University of College London think a predicti...
FEB 19, 2020
Immunology
FEB 19, 2020
Testing the Immune Response to Ovarian Cancer Treatment
There is a new diagnostic test for the deadliest form of gynecological cancer – ovarian cancer. Better tests mean better diagnostics, and better diag...
Loading Comments...